Dr. John Anderson -- Pharma Payment Report

Payment Summary

• Total Payments Received: $71,984.52
• Number of Transactions: 1
• Transparency Score: 50/100

Payment Breakdown

• speaking: $0.00
• travel: $0.00
• ownership: $0.00
• consulting: $0.00
• research: $71,984.52
• meals: $0.00

AI Analysis

Dr. John Anderson, an ophthalmologist in Springfield, IL, has a pharmaceutical payment profile characterized by a single, substantial payment. With a total of $71,984.52 received from pharmaceutical companies, this amount stands out due to its singular nature and significant value. The entirety of this payment originates from Johnson & Johnson, designated for research activities in 2025. This concentration of payment from a single entity for a specific purpose, research, is a key feature of Dr. Anderson's financial interactions with the pharmaceutical industry. Comparing Dr. Anderson's total payment volume to peers in ophthalmology requires careful consideration. While a single payment of over $70,000 is substantial, the absence of other payments means his overall annual engagement might be lower than ophthalmologists who receive numerous smaller payments for consulting, speaking, or meals throughout the year. The average ophthalmologist may receive payments spread across multiple companies and for various services. Therefore, while this single payment is large, it doesn't necessarily place him at the highest end of total annual compensation from industry. The fact that the payment is for research is also a critical distinction. Research payments are often tied to clinical trials or the development of new treatments, which can be a legitimate and valuable part of medical advancement. However, the scale of this payment warrants understanding the nature of the research and its potential impact. The payment breakdown for Dr. Anderson is heavily skewed towards research, with no reported income from consulting, speaking, meals, or travel. This suggests that his engagement with Johnson & Johnson is specifically for research-related endeavors. This pattern, while involving a significant sum, is distinct from doctors who receive regular, smaller payments for activities that might be perceived as influencing prescribing habits, such as frequent meals or consulting fees. The singular nature of this payment, rather than a pattern of multiple engagements, makes it less indicative of routine professional activity and more of a specific, potentially project-based, research collaboration. Patients should be aware that while research funding is crucial for medical progress, understanding the specific research being conducted and its potential benefits and risks is important. This payment, in isolation, does not automatically imply a compromise in patient care but highlights a significant financial tie to a specific pharmaceutical company for research purposes.

Patient Guidance

When considering your doctor's financial relationships with pharmaceutical companies, it's helpful to be informed. A single, large payment for research, like Dr. Anderson's with Johnson & Johnson, is different from a pattern of frequent, smaller payments for consulting or meals. At your next appointment, you might consider asking: 'Are you involved in any research funded by pharmaceutical companies?' or 'Do you receive any payments or benefits from drug manufacturers?' While doctors are not obligated to disclose every detail, these questions can open a dialogue. Red flags to watch for include a doctor who consistently prescribes a specific brand-name drug without a clear clinical justification, especially if they have significant financial ties to that drug's manufacturer. It's also concerning if a doctor seems overly promotional about a particular medication or treatment. Normal pharma relationships often involve payments for legitimate research, speaking at educational events, or providing expert consultation on drug development. These can be beneficial for advancing medical knowledge. However, relationships become concerning when they appear to influence prescribing habits away from the best interests of the patient, such as favoring expensive brand-name drugs over equally effective generics when there's no clear medical reason. Evaluating your doctor's prescribing patterns in light of payments involves looking for consistency and appropriateness. If your doctor prescribes a medication that seems unusual or overly expensive, and you know they have a financial tie to that company, it's reasonable to seek a second opinion or ask for a detailed explanation of why that specific treatment is necessary.

Peer Comparison

The average ophthalmologist receives payments from pharmaceutical companies that vary widely, but typically involve multiple smaller transactions for consulting, speaking, and meals. While some ophthalmologists engage in significant research collaborations, a single research payment of $71,984.52 is notable. Without other reported payments, Dr. Anderson's overall annual engagement might be lower than peers who receive more frequent, smaller payments. This specific payment for research places him in a different category than those with broader industry interactions.

Recent Payments

Frequently Asked Questions

Is Dr. John Anderson taking too much pharma money?

Dr. Anderson received a single payment of $71,984.52 for research from Johnson & Johnson. While this is a substantial amount for a single transaction, it's crucial to consider the context. Unlike doctors who receive numerous smaller payments for consulting or meals, Dr. Anderson's profile shows a singular focus on research funding. This type of payment is often tied to clinical trials or drug development, which can be a legitimate part of medical advancement. Without a pattern of multiple payments or payments for activities that might influence prescribing, it's difficult to definitively label this as 'too much' money. The key is the nature and purpose of the payment.

What pharma companies pay Dr. John Anderson?

Dr. John Anderson receives payments exclusively from Johnson & Johnson. The total amount paid by Johnson & Johnson is $71,984.52. This payment is specifically designated for research activities.

Should I switch doctors because of pharma payments?

Switching doctors solely based on pharmaceutical payments should be a nuanced decision. A single, large payment for research, as seen with Dr. Anderson, is less concerning than a pattern of frequent, smaller payments for consulting or meals, which might raise questions about potential influence on prescribing. If your doctor has a clear financial relationship with a company whose drugs they frequently prescribe without clear justification, or if you feel their treatment recommendations are influenced by these relationships, then seeking a second opinion or considering a new doctor might be warranted. However, if the payments are for legitimate research or educational activities and your care remains excellent, it may not be a reason to switch.

What kinds of payments does this doctor receive?

Dr. John Anderson's payment profile indicates that all reported funds come from research activities. There are no reported payments for consulting, speaking engagements, meals, or travel from pharmaceutical companies. This suggests his financial interaction with the industry is specifically tied to research endeavors.

How do these payments compare to other Ophthalmology?

The average ophthalmologist may receive payments from various pharmaceutical companies for a range of activities like consulting, speaking, and meals. Dr. Anderson's profile shows a single, significant payment for research. While this amount is substantial for one transaction, his overall annual engagement with the industry might be less frequent than peers who receive multiple smaller payments. This research-focused payment distinguishes his profile from the typical, more diversified payment patterns seen in the specialty.

Do pharma payments affect prescribing quality?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns, often leading to increased prescription of brand-name drugs and higher overall prescribing costs. However, the impact varies depending on the type and magnitude of the payment. Payments for research, like Dr. Anderson's, are intended to advance medical knowledge and may not directly correlate with individual patient prescribing decisions in the same way that consulting or speaking fees might. It's important to consider the totality of a doctor's interactions and their clinical judgment.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This publicly accessible website allows you to search for physicians and teaching hospitals to view their reported financial relationships with the pharmaceutical and medical device industries. You can input Dr. John Anderson's NPI (1845440705) to find the detailed records of payments made to him.